Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3767125 | 0.91 | CYP19A1 (0.53) | CNR2MAPTMAPK1HDAC6HDAC1 | |
| SCHEMBL13011637 | 0.88 | CNR2 (0.56) | CNR2MAPTMAPK1L3MBTL1HDAC6 | |
| SCHEMBL13011683 | 0.86 | P2RX4 (0.52) | MAPTMAPK1L3MBTL1HDAC6HDAC1 | |
| SCHEMBL13062047 | 0.84 | P2RX4 (0.55) | CNR2MAPK1HDAC6HDAC1HDAC10 | |
| SCHEMBL13011636 | 0.83 | CNR2 (0.54) | CNR2HTR2BHTR7 | |
| SCHEMBL13011744 | 0.82 | HTR2B (0.43) | CNR2HDAC6HDAC1HDAC10HDAC2 | |
| SCHEMBL13011698 | 0.82 | HDAC6 (0.44) | MAPK1HDAC6HDAC1HDAC10HDAC2 | |
| SCHEMBL13061912 | 0.81 | KDM4E (0.44) | CNR2MAPTHDAC6HDAC1HDAC10 | |
| SCHEMBL3777210 | 0.81 | HTR2B (0.46) | MAPTHDAC6HDAC1HDAC10HTR2B | |
| SCHEMBL13061918 | 0.81 | TP53 (0.47) | MAPTHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | CNR2 681/4885MAPT 348/4885MAPK1 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.